Although it is undeniable that E2F1 acts as oncogene in several cancers, including in melanoma, to the extent that it has been proposed as a new therapeutic target [20], it is not clear which molecular mechanism triggers the transcription of E2F1 and consequently lead to the neoplastic transformation of melanocytes. Here, E2F1 is linked to cancer.